--------------------------------------------------------------------------------
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
--------------------------------------------------------------------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of the Earliest Event Reported: July 31, 2003
Date of Report: July 31, 2003
RIBAPHARM INC.
(Exact name of registrant as specified in its charter)
Delaware 1-31294 95-4805665
-------- ------- ----------
(State or other jurisdiction of (Commission (I.R.S. Employer
incorporation or organization) file number) Identification No.)
3300 Hyland Avenue
Costa Mesa, California 92626
(Address of principal executive offices) (Zip code)
(714) 427-6236
(Registrant's telephone
number, including area code)
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
-1-
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
(c) Exhibits
Exhibit No. Description
----------- -----------
99.1 Press Release dated July 31, 2003
Item 12. Results of Operations and Financial Condition.
On July 31, 2003, Ribapharm Inc. issued a press release announcing its
second fiscal quarter results ended June 30, 2003 and will hold a conference
call on such date. The press release is attached as Exhibit 99.1.
-2-
SIGNATURE
---------
Pursuant to the requirements of the Securities Exchange Act of 1934,
Ribapharm Inc. has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: July 31, 2003 RIBAPHARM INC.
/s/ KIM D. LAMON
--------------------------------------
President and Chief Executive Officer
-3-
EXHIBIT INDEX
Exhibit No. Description
----------- -----------
99.1 Press Release dated July 31, 2003
-4-